Research Article

Overexpression of MAL2 Correlates with Immune Infiltration and Poor Prognosis in Breast Cancer

Table 2

Clinical characteristics of TCGA breast cancer cohort.

CharacteristicsNumber of sample size (%)

Age
<4075 (6.88)
≥401015 (93.12)

Gender
Female1079 (98.90)
Male12 (1.10)

Stage
I182 (16.70)
II620 (56.88)
III249 (22.84)
IV21 (1.93)
X18 (1.65)

T classification
T1280 (25.69)
T2630 (57.80)
T3138 (12.66)
T439 (3.58)
TX3 (0.28)

M classification
M0900 (82.57)
M122 (2.02)
MX168 (15.41)

N classification
N0484 (44.40)
N1390 (35.78)
N2180 (16.51)
N327 (2.48)
NX9 (0.83)

ER status
Negative236 (21.65)
Positive805 (73.85)
Unknown49 (4.50)
PR status343 (31.47)
Negative695 (63.76)
Positive52 (4.77)
Unknown559 (51.28)
HER2 status163 (14.95)
Negative368 (33.76)
Positive236 (21.65)
Unknown805 (73.85)
Vital status
Living941 (86.33)
Deceased149 (13.67)

MAL2 expression
High545 (50.00)
Low545 (50.00)

NA, not available.